Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosis.

MLA

Li, Jieni, et al. “Factors Associated with the Initiation of High-Efficacy Disease-Modifying Agents over Moderate-Efficacy Disease-Modifying Agents in Multiple Sclerosis.” Multiple Sclerosis and Related Disorders, vol. 91, Nov. 2024, p. 105896. EBSCOhost, https://doi.org/10.1016/j.msard.2024.105896.

APA

Li, J., Hutton, G. J., Varisco, T. J., Lin, Y., Essien, E. J., & Aparasu, R. R. (2024). Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosis. Multiple Sclerosis and Related Disorders, 91, 105896. https://doi.org/10.1016/j.msard.2024.105896

Chicago

Li, Jieni, George J Hutton, Tyler J Varisco, Ying Lin, Ekere J Essien, and Rajender R Aparasu. 2024. “Factors Associated with the Initiation of High-Efficacy Disease-Modifying Agents over Moderate-Efficacy Disease-Modifying Agents in Multiple Sclerosis.” Multiple Sclerosis and Related Disorders 91 (November): 105896. doi:10.1016/j.msard.2024.105896.